Advertisement

Picture Berlin Partner Voices Martin Rahmel TU Berlin GreenChem 650x100px
Organisation › Details

Immatics N.V. (Nasdaq: IMTX)

Period Start 2020-03-17 planned
  Group Immatics (Group)
Products Industry cancer drug
  Industry 2 ACTengine® cell therapy product
Persons Person Singh, Harpreet (Immatics 201907– CEO before CSO + CEO of Immatics US + Co-Founder)
  Person 2 Christ, Arnd (Immatics 202010– CFO before InflaRx + Proteros + MediGene + NovImmune + Probiodrug + Hoechst)
     
Region Region Netherlands_oo
  Country Netherlands
  City n. a. 
    Address record changed: 2020-03-19
     
Basic data Employees E: 501 to 1,000 (2023-12-31)
  Currency EUR
  Annual sales 53,997,000 (revenue, consolidated (2023) 2023-12-31)
  Profit -96,994,000 (2023-12-31)
  Cash 425,895,000 (2023-12-31)
     
     
   
Record changed: 2024-03-22

Advertisement

Picture EBD Group World of Partnering Opportunities 650x200px

More documents for Immatics (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture Sino Biological Symposium Antibody Engineering Leipzig 650x300px




» top